Answers are grounded in this paper and cite their sources.
Economic evaluation shows adding vancomycin does not improve outcomes in arthroplasty, suggesting cost savings by omitting it.
Adding vancomycin to cephazolin prophylaxis in arthroplasty is most likely not cost-effective. Omitting vancomycin could lead to substantial annual savings for the healthcare sector without compromising health outcomes.
No takes yet. Share an insight, caveat, or question.
Tran-Duy et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: